|
Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2. |
| |
|
Leadership - Interpark Bio; J Ints Bio |
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance |
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; CJ bioscience; CureLogen; Cyrus therapeutics; GI Cell; Guardant Health; Hanmi; Imnewrun; inno.N; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Onegene Biotechnology; Ono Pharmaceutical; Oscotec; Pfizer; RandBio; Roche; Takeda; Yuhan |
Research Funding - Abbvie; Abion; AstraZeneca; Bayer; Blueprint medicines; Boehringer Ingelheim; Bridgebio; CHA Bundang Medical Center; Champions Oncology; CJ bioscience; CJ Blossom Park; Cyrus Therapeutics; Dizal Pharma; Dong-A ST; Genexine; GI Cell; GI Innovation; Hanmi; Illumina; ImmuneOncia; Interpark Bio; J Ints Bio; Janssen; Kanaph therapeutics; LG Chem; Lilly; Mogam Biotechnology Research Institue; MSD; Novartis; Nuvalent, Inc.; Oncternal Therapeutics; Ono Pharmaceutical; Oscotec; Regeneron; Therapex; Yuhan |
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen |
Other Relationship - DAAN Biotherapeutics |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics |
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology |
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche |
Other Relationship - GRIFOLS |
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023 |
| |
|
No Relationships to Disclose |
| |
|
Leadership - Next Oncology (Inst) |
Stock and Other Ownership Interests - Lilly |
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda |
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda |
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst) |
| |
|
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; HMP Education; Medical Educator Consortium; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME |
Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; D2G Oncology; Exelixis; Genentech/Roche; Gilead Sciences; Iovance Biotherapeutics; Janssen Oncology; Lilly; Mirati Therapeutics; Natera; Novartis; Novocure; Regeneron; Sanofi/Regeneron; Summit Therapeutics; Surface Oncology; Takeda; Turning Point Therapeutics |
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Takeda (Inst) |
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Johnson & Johnson; Merck |
Honoraria - AstraZeneca; Blueprint Medicines; Janssen Oncology; Novocure; Takeda; Thermo Fisher Scientific |
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb/Celgene; Ikena Oncology; Janssen Oncology; Regeneron |
Research Funding - AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Regeneron |
| |
|
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda |
Research Funding - Janssen |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Amgen; AstraZeneca/MedImmune; Lilly; Merck Sharp & Dohme; Roche; Yuhan |
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; BMS/Ono; Daiichi Sankyo; IMBdx; ImmuneOncia; Janssen; Lilly; Merck (German); Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda |
|
Research Funding - AstraZeneca (Inst); Lunit (Inst); Merck Sharp & Dohme (Inst) |
| |
|
Honoraria - Amgen (Inst); AstraZeneca; AstraZeneca/MedImmune (Inst); BeiGene (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca (Inst); Dizal Pharma (Inst); Gilead Sciences (Inst); Lilly; MSD; MSD Oncology (Inst); Novartis; Ono Pharmaceutical; Pfizer; Pfizer (Inst); Roche; Roche/Genentech (Inst); Sanofi/Regeneron (Inst); Taiho Pharmaceutical (Inst); Takeda; Takeda (Inst) |
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Bayer (Inst); Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca (Inst); G1 Therapeutics; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen Oncology (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda; Takeda (Inst); Yuhan |
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - Pfizer |
| |
Sebastian Yves Friedrich Michels |
Honoraria - AstraZeneca; Janssen Oncology; Novartis; Takeda |
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Novartis; Takeda |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Janssen Oncology; Lilly |
| |
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
| |
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
| |
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
| |
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
| |
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
| |
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb Foundation; Janssen; Roche; Takeda |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Pfizer; Takeda |